- La presente analisi epidemiologica ha valutato i pazienti con psoriasi pustolosa arruolati dalla Japanese Society for Psoriasis Research (JSPR) dal 2017 al 2020.
- Il 58,4% dei pazienti sono stati trattati con farmaci orali e il 4,0% con biologici. Il farmaco orale maggiormente prescritto è stato l’etretinato (52,4%), seguito dai corticosteroidi (24,7%) e dalla ciclosporina (22,9%). I biologici più utilizzati sono stati gli inibitori dell’IL-17 (ixekizumab [28,1%] e secukinumab [22,7%]), seguiti dagli inibitori del TNF (infliximab [15,6%]) e dell’IL-23 (guselkumab [14,8%] e risankizumab [10,2%]).
Abstract
The Japanese Society for Psoriasis Research (JSPR) has been conducting annual epidemiological surveys of patients with pustular psoriasis in Japan since 2017. This study aimed to conduct a recent epidemiological analysis of patients with pustular psoriasis who were enrolled in the JSPR from 2017 to 2020. A total of 291 patients from 131 medical institutions were enrolled, of which 47.4% (138 cases) were males and 52.6% (153 cases) were females. The mean ± standard deviation (SD) age of the patients was 57.4 ± 20.3 years (males, 61.2 ± 17.3 years; females, 54.1 ± 22.1 years). The mean ± SD age of the patients at disease onset was 48.5 ± 22.5 years (males, 50.8 ± 20.6 years; females, 46.4 ± 24.0 years). The types of pustular psoriasis observed included the von Zumbusch type (59.8%), annular pustular psoriasis (8.2%), impetigo herpetiformis (6.5%), and acrodermatitis continua of Hallopeau (4.8%), of which, the majority of the patients with impetigo herpetiformis were female. Among the patients, 58.4% were treated with oral medications and 44.0% were treated with biologics. The most common oral medication prescribed was etretinate (52.4%), followed by corticosteroids (24.7%) and cyclosporin (22.9%). The most common biologics used were IL-17 inhibitors (ixekizumab [28.1%] and secukinumab [22.7%]), followed by tumor necrosis factor (TNF) inhibitors (infliximab [15.6%]) and IL-23 inhibitors (guselkumab [14.8%] and risankizumab [10.2%]). This survey thus provides new and significant information regarding the recent perspective of pustular psoriasis, such as patient characteristics and treatment trends, in Japan.